These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8198024)

  • 1. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.
    Herd JA; West MS; Ballantyne C; Farmer J; Gotto AM
    Am J Cardiol; 1994 May; 73(14):42D-49D. PubMed ID: 8198024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
    West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
    Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
    Herd JA
    Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
    Peters TK
    Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
    Herd JA; Ballantyne CM; Farmer JA; Ferguson JJ; Jones PH; West MS; Gould KL; Gotto AM
    Am J Cardiol; 1997 Aug; 80(3):278-86. PubMed ID: 9264419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group.
    Jacotot B; Banga JD; Waite R; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):41A-46A. PubMed ID: 7604796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
    Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
    Levy RI; Troendle AJ; Fattu JM
    Circulation; 1993 Apr; 87(4 Suppl):III45-53. PubMed ID: 8462180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
    Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P
    Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study.
    Marian AJ; Safavi F; Ferlic L; Dunn JK; Gotto AM; Ballantyne CM
    J Am Coll Cardiol; 2000 Jan; 35(1):89-95. PubMed ID: 10636265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
    Peters TK; Muratti EN; Mehra M
    Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
    Goldberg RB; Roth D
    Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.